Menu Search
Equities

Physiomics PLC

RVW1:FRA

Physiomics PLC

Actions
  • Price (EUR)0.012
  • Today's Change0.001 / 4.35%
  • Shares traded-1.00
  • 1 Year change-57.14%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 20:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.

  • Revenue in GBP (TTM)633.35k
  • Net income in GBP-451.26k
  • Incorporated2001
  • Employees10.00
  • Location
    Physiomics PLCBee House140 Eastern Avenue, Milton ParkOXFORD OX14 4SBUnited KingdomGBR
  • Phone+44 123 584 1575
  • Fax+44 870 167 1931
  • Websitehttps://www.physiomics.co.uk/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.